PPAC2: Packing of Perianal Abscess Cavities

Sponsor
Manchester University NHS Foundation Trust (Other)
Overall Status
Completed
CT.gov ID
NCT03315169
Collaborator
Liverpool Clinical Trials Unit (Other), Northwest Research Collaborative (Other), University of Birmingham (Other), National Institute for Health Research, United Kingdom (Other)
433
50
2
27.9
8.7
0.3

Study Details

Study Description

Brief Summary

The aim of this trial is to compare internal wound packing to no packing in postoperative management following incision and drainage of perianal abscess. Participants will be randomised 1:1 to either the packing or non-packing arm.

Condition or Disease Intervention/Treatment Phase
  • Other: External dressing
  • Other: Packing of perianal abscess cavity
N/A

Detailed Description

Perianal abscess is common, affecting 18,000 patients annually in England. Management has remained largely unchanged for over 50 years, and comprises surgical incision and drainage followed by continued internal wound dressing (packing) until healed. Packing is thought to reduce the rate of recurrent abscess and perianal fistula; a known complication of perianal abscess. Perianal fistula frequently requires multiple operations to resolve. The evidence for postoperative packing is limited¹ and may expose patients to painful procedures with no clinical benefit, and at considerable increased cost².

A multi-centre observational study of outcomes after drainage of perianal abscess (PPAC²) (n=141) found packing to be painful (2-3 fold increase in Visual Analogue Score pain scores during packing) and costly (estimated cost of £280 per patient; overall cost in the United Kingdom of £5 million annually). Fistula rate was 27%.

This study is a randomised controlled trial designed to assess whether there are differences between non-packing and packing of the perianal abscess cavity in terms of the short term negative effects of packing (pain, quality of life, return to work) whilst assessing the impact on key clinical outcomes (wound healing, fistulae formation) and resource use/cost.

All participants will be required to complete pain diaries following discharge from hospital. Clinical follow up to assess healing and other key clinical outcomes will take place at 4, 8 (if not healed at 4 weeks) and 26 weeks. Further data will be collected from National Health Service Registries at 52 weeks in order to assess abscess recurrences and fistulae formation.

Study Design

Study Type:
Interventional
Actual Enrollment :
433 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Note that only the clinician assessing healing and fistulae are masked.
Primary Purpose:
Treatment
Official Title:
The Impact of Postoperative Packing of Perianal Abscess Cavities: a Multicentre Randomised Controlled Trial
Actual Study Start Date :
Feb 14, 2018
Actual Primary Completion Date :
Jun 12, 2020
Actual Study Completion Date :
Jun 12, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Packing of perianal abscess cavity

Internal packing of perianal abscess cavity as per normal practice.

Other: Packing of perianal abscess cavity
Internal packing of perianal abscess cavity - standard treatment.

Experimental: External dressing

External application of a non-adherent dressing to the perianal abscess cavity.

Other: External dressing
Application of external dressing whilst perianal abscess cavity heals.

Outcome Measures

Primary Outcome Measures

  1. Wound-related pain intensity [Mean score over first 10 post-operative days]

    Wound-related pain intensity (worst pain during previous 24 hours) measured using a single 100mm Visual Analogue Scale where 0 represents 'no pain' and 100 represents 'worst pain possible'. The pain Visual Analogue Scale is a continuous scale comprised of a horizontal line 100mm in length, anchored by 2 verbal descriptors, one for each symptom extreme, where 0 represents 'no pain' and 100 represents 'worst pain possible'. The mean score over the first 10 post-operative days will be used.

Secondary Outcome Measures

  1. Dressing-change related pain intensity [First 10 post-operative days]

    Pain before, during and after dressing change measured using a 100mm Visual Analogue Scale where 0 represents 'no pain' and 100 represents 'worst pain possible'. The pain Visual Analogue Scale is a continuous scale comprised of a horizontal line 100 mm in length, anchored by 2 verbal descriptors, one for each symptom extreme. The mean score for each timepoint (before, during and after) over the first 10 post-operative days will be used.

  2. Health related quality of life [On the 21st post-operative day]

    Health related quality of life measured using EuroQol EQ-5D-5L quality of life questionnaires. The EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension now has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.

  3. Health utility [On the 21st post-operative day]

    Health utility measured using EuroQol EQ-5D-5L quality of life questionnaires. The EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension now has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.

  4. Patient satisfaction with wound management [On the 21st post-operative day]

    Patient satisfaction with wound management measured using a five point Likert scale. Patients are asked to mark the extent to which they agree with the statement 'I am satisfied with the way my wound has been treated following my surgery' where 1 equates to 'strongly disagree' and 5 equates to 'strongly agree'.

  5. Rate of wound healing [Four and eight weeks post-operatively]

    Rate of wound healing (complete epithelialization)

  6. Clinical diagnosis of perianal abscesses recurrence after healing [52 weeks post-operatively]

    Clinical diagnosis of perianal abscesses recurrence after healing, ascertained either through clinical follow-up as part of trial procedures or via central National Health Service registries.

  7. Chronic post-surgical pain [4, 8 and 26 weeks post-operatively]

    Chronic post-surgical pain measured using the Brief Pain Inventory - Short Form. The Brief Pain Inventory - Short Form assesses the severity of pain and the impact on daily functions. Pain is assessed at its "worst," "least," "average," and "now" (current pain), measured on a scale of 1-10 where 1 represents "no pain" and 10 represents "pain as bad as you can imagine". The four items will be represented singly but a composite of the four pain items (a mean score) will be presented as supplemental information. Pain interference (impact of pain on seven daily activities) will be scored as the mean of the seven interference items. These items are scored between 1 and 10, where 1 represents "does not interfere" and 10 represents "completely interferes".

  8. Dressing use [Up to 52 weeks post-operatively]

    Number of dressings used between time of operation up until week 52.

  9. Health Professional contact time [Up to 52 weeks post-operatively]

    Number of contacts with a Health Professional regarding perianal abscess or post-surgical complications between time of operation and 52 weeks post-operatively.

  10. Hospital admission time [Up to 52 weeks post-operatively]

    Number and length of hospital admissions as recorded in NHS central registries - Hospital Episodes Statistics.

  11. Time to return to work or normal function [Up to 52 weeks post-operatively]

    Length of time, measured in days, between operation and return to work or normal function.

  12. Cost [Up to 52 weeks post-operatively]

    Cost as applied to resource use data (see outcome 9-12)

  13. Assessment of pain control methods [21 days post-operatively]

    Assessment of pain control methods (i.e. pain control medications) using Patient Global Assessment of the method of pain control where a rating of the pain control method over the past 24 hours is rated as being one of "poor," "fair," "good," or "excellent".

  14. Fistula rate [Up ro 52 weeks post-operatively]

    Fistula rate observed during clinical follow up and through Hospital Episodes Statistics

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged 18 or over

  2. Undergoing surgical incision and drainage of a primary perianal abscess

Exclusion Criteria:
  1. Suspected inflammatory bowel disease

  2. Fournier's Gangrene

  3. Horseshoe (bilateral) abscess

  4. Fistula-in-ano

  5. Multiple abscess

Contacts and Locations

Locations

Site City State Country Postal Code
1 Salford Royal Hospital Salford Greater Manchester United Kingdom M6 8HD
2 West Middlesex University Hospital (Isleworth) Isleworth Middlesex United Kingdom TW7 6AF
3 John Radcliffe Hospital Oxford Oxfordshire United Kingdom OX3 9DZ
4 Mew Cross Hospital Wolverhampton West Midlands United Kingdom WV10 0QP
5 Huddersfield Royal Infirmary Huddersfield West Yorkshire United Kingdom HD3 3EA
6 Pindersfields General Hospital Wakefield West Yorkshire United Kingdom WF1 4DS
7 Salisbury District Hospital Salisbury Wiltshire United Kingdom SP2 8BJ
8 Aberdeen Royal Infirmary Aberdeen United Kingdom
9 Bangor Hospital, Betsi Cadwaladr University Health Board Bangor United Kingdom
10 Furness General Hospital Barrow In Furness United Kingdom
11 Royal United Hospital Bath NHS Foundation Trust Bath United Kingdom
12 Birmingham Heartlands Hospital Birmingham United Kingdom
13 Queen Elizabeth Hospital Birmingham Birmingham United Kingdom
14 Royal Blackburn Hospital Blackburn United Kingdom
15 Blackpool Victoria Hospital Blackpool United Kingdom
16 Royal Bolton Hospital Bolton United Kingdom
17 Bristol royal Infirmary, University Hospitals Bristol Bristol United Kingdom
18 Southmead Hospital North Bristo; NHS Trust Bristol United Kingdom
19 Addenbrooke's Hospital Cambridge United Kingdom
20 University Hospital of Wales (Cardiff) Cardiff United Kingdom
21 Broomfield Hospital Chelmsford United Kingdom
22 Chesterfield Royal Hospital NHS Foundation Trust Chesterfield United Kingdom
23 Countess of Chester Chester United Kingdom CH2 1UL
24 University Hospitals Coventry and Warwickshire Coventry United Kingdom
25 Royal Devon & Exeter Hospital Exeter United Kingdom
26 Victoria Hospital (Fife) Kirkcaldy United Kingdom
27 Royal Lancaster Infirmary Lancaster United Kingdom
28 Aintree Hospital Liverpool United Kingdom
29 Royal Liverpool and Broadgreen University Hospitals NHS Trust Liverpool United Kingdom
30 Royal Glamorgan Hospital Llantrisant United Kingdom
31 Macclesfield District General Hospital Macclesfield United Kingdom
32 Manchester Royal Infirmary Manchester United Kingdom
33 Wythenshawe Hospital Manchester United Kingdom
34 Queen Elizabeth The Queen Mother Hospital Margate United Kingdom
35 Newcastle Upon Tyne University Hospitals NHS Foundation Trust Newcastle United Kingdom
36 Royal Gwent Hospital Newport United Kingdom
37 Norfolk and Norwich University Hospital Norwich United Kingdom
38 Nottingham University Hospitals NHS Trust Nottingham United Kingdom
39 Royal Alexandra Hospital Paisley United Kingdom
40 Plymouth Hospitals NHS Trust Derriford Hospital Plymouth United Kingdom
41 Portsmouth Hospitals NHS Trust Portsmouth United Kingdom
42 Sheffield Teaching Hospitals NHS Foundation Trust Sheffield United Kingdom
43 Southampton General Hospital Southampton United Kingdom
44 Arrowe Park Hospital Upton United Kingdom
45 Warrington Hospital Warrington United Kingdom
46 Warwick Hospital, South Warwickshire NHS Foundation Trust Warwick United Kingdom
47 Sandwell Hospital, SWBH NHS Trust West Bromwich United Kingdom
48 Royal Albert and Edward Infirmary Wigan United Kingdom
49 Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board Wrexham United Kingdom
50 Yeovil District Hospital Yeovil United Kingdom

Sponsors and Collaborators

  • Manchester University NHS Foundation Trust
  • Liverpool Clinical Trials Unit
  • Northwest Research Collaborative
  • University of Birmingham
  • National Institute for Health Research, United Kingdom

Investigators

  • Principal Investigator: James Hill, FRCS, Manchester University NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Manchester University NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT03315169
Other Study ID Numbers:
  • R04689
  • PB-PG-0815-20037
First Posted:
Oct 20, 2017
Last Update Posted:
Sep 9, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Manchester University NHS Foundation Trust
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 9, 2020